Moleculin Biotech, Inc. is a pre-clinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Tackling the most difficult cancers…

By reducing the activity of certain tumor supporting transcription factors, tumor cells lose their ability to survive and reproduce.  By increasing the activity of other transcription factors, WP1066 actually calls the patient’s natural immune system into action.  Importantly, this has been shown in some of the most difficult cancers to treat, such as pancreatic cancer and metastatic melanoma.

For further information on WP1066, click here.

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates regarding Moleculin and breakthrough Cancer related innovations!

You have Successfully Subscribed!